Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2 2018
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H2 2018'; Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is an enzyme that is encoded by the DYRK1A gene. DYRK1A autophosphorylates on tyrosine serine and threonine residues but phosphorylate substrates only on serine or threonine residues. It plays a significant role in a signaling pathway regulating cell proliferation and involved in brain development.
The report 'Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H2 2018' outlays comprehensive information on the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects.
Currently, The molecules developed by companies in Preclinical and Discovery stages are 9 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Metabolic Disorders, Oncology and Immunology which include indications Alzheimer's Disease, Down Syndrome, Type 1 Diabetes (Juvenile Diabetes), Autoimmune Disorders, Colon Cancer, Dementia, Depression, Glioblastoma Multiforme (GBM), Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD) and Prostate Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H2 2018'; Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is an enzyme that is encoded by the DYRK1A gene. DYRK1A autophosphorylates on tyrosine serine and threonine residues but phosphorylate substrates only on serine or threonine residues. It plays a significant role in a signaling pathway regulating cell proliferation and involved in brain development.
The report 'Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H2 2018' outlays comprehensive information on the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects.
Currently, The molecules developed by companies in Preclinical and Discovery stages are 9 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Metabolic Disorders, Oncology and Immunology which include indications Alzheimer's Disease, Down Syndrome, Type 1 Diabetes (Juvenile Diabetes), Autoimmune Disorders, Colon Cancer, Dementia, Depression, Glioblastoma Multiforme (GBM), Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD) and Prostate Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)
- The report reviews Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Overview
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Companies Involved in Therapeutics Development
Carna Biosciences Inc
Felicitex Therapeutics Inc
ManRos Therapeutics
NeuroNascent Inc
Pharmasum Therapeutics AS
Samumed LLC
SanBio Co Ltd
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Drug Profiles
ABI-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABI-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-9847 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NNI-351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PST-1100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PST-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-07883 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to inhibit DYRK1A for Alzheimer's and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Parkinson's Disease and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dormant Products
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Discontinued Products
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Product Development Milestones
Featured News & Press Releases
Jul 27, 2018: Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer's Association International Conference
Jul 17, 2018: Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer's Disease Candidate, at the Alzheimer's Association International Conference 2018
Aug 28, 2017: Avanti Biosciences Receives $1.9M SBIR Fast-Track Award to Further Treatment for Alzheimer’s disease
Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics
Mar 20, 2013: BIO5-TGen Collaboration Focused On Drug Development For Alzheimer’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Overview
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Companies Involved in Therapeutics Development
Carna Biosciences Inc
Felicitex Therapeutics Inc
ManRos Therapeutics
NeuroNascent Inc
Pharmasum Therapeutics AS
Samumed LLC
SanBio Co Ltd
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Drug Profiles
ABI-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABI-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-9847 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NNI-351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PST-1100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PST-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-07883 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to inhibit DYRK1A for Alzheimer's and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Parkinson's Disease and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dormant Products
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Discontinued Products
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Product Development Milestones
Featured News & Press Releases
Jul 27, 2018: Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer's Association International Conference
Jul 17, 2018: Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer's Disease Candidate, at the Alzheimer's Association International Conference 2018
Aug 28, 2017: Avanti Biosciences Receives $1.9M SBIR Fast-Track Award to Further Treatment for Alzheimer’s disease
Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics
Mar 20, 2013: BIO5-TGen Collaboration Focused On Drug Development For Alzheimer’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Carna Biosciences Inc, H2 2018
Pipeline by Felicitex Therapeutics Inc, H2 2018
Pipeline by ManRos Therapeutics, H2 2018
Pipeline by NeuroNascent Inc, H2 2018
Pipeline by Pharmasum Therapeutics AS, H2 2018
Pipeline by Samumed LLC, H2 2018
Pipeline by SanBio Co Ltd, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Carna Biosciences Inc, H2 2018
Pipeline by Felicitex Therapeutics Inc, H2 2018
Pipeline by ManRos Therapeutics, H2 2018
Pipeline by NeuroNascent Inc, H2 2018
Pipeline by Pharmasum Therapeutics AS, H2 2018
Pipeline by Samumed LLC, H2 2018
Pipeline by SanBio Co Ltd, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Carna Biosciences Inc
Felicitex Therapeutics Inc
ManRos Therapeutics
NeuroNascent Inc
Pharmasum Therapeutics AS
Samumed LLC
SanBio Co Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Carna Biosciences Inc
Felicitex Therapeutics Inc
ManRos Therapeutics
NeuroNascent Inc
Pharmasum Therapeutics AS
Samumed LLC
SanBio Co Ltd
